Merck says Keytruda could be up next for IRA price cuts
Merck said its “once-in-a-lifetime” drug Keytruda could be subject to price reductions under the Inflation Reduction Act, which would lead to a decline in sales. It expects Keytruda to be chosen for ...
View ArticleGinkgo uncertain over the future of US government funding, stock drops
Ginkgo Bioworks’ stock $DNA fell by around 13% premarket Wednesday after the company dampened its 2025 sales forecast. “We are being conservative with our revenue guidance in 2025 given uncertainty...
View ArticleUpdated: Lilly joins Trump administration to announce $27B manufacturing...
WASHINGTON — Eli Lilly touted a huge new US manufacturing investment at an event on Wednesday, trotting out the news with a member of President Donald Trump’s cabinet as part of what has been a...
View ArticleHarbour BioMed inks deal up to $395M; ORIC refines plans for two drugs
Plus, news about Idorsia, Enveda, Zymeworks, BerGenBio and Ignota Labs: Harbour BioMed does another deal: The Shanghai-based biotech’s subsidiary, called HBM Alpha Therapeutics, inked a pact with an...
View ArticleRegeneron, two Chinese biotechs tout promise of their hearing loss gene...
Several small clinical trials have demonstrated that gene therapies have restored hearing in children with a rare form of genetic deafness. In an update at the Association for Research in...
View ArticleAstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line...
AstraZeneca wasn't expected to have data from the Phase 3 trial of its oral SERD until the second half of this year so the positive interim results that the UK drugmaker
View ArticleRegeneron shakes up accelerated approval plans for lymphoma bispecific
Regeneron is now expecting an accelerated approval decision this summer on its T cell engager for one form of lymphoma, while it's giving up on accelerated approval for a different form of the disease....
View ArticleMedicare spending on set of diabetes drugs skyrocketed — report
The use of a subset of common diabetes drugs skyrocketed in the US Medicare program over a five-year period ending in 2023, according to a new report from the HHS inspector general. The
View ArticleFDA meeting to pick next winter's flu shot is canceled
A meeting by a panel of science advisors to choose flu strains to include in a vaccine for next fall has been canceled on short notice, according to a member of the committee, raising concerns ...
View ArticleSorriso Pharmaceuticals outlines Phase 1b ulcerative colitis data for oral...
Private startup Sorriso Pharmaceuticals laid out Phase 1b data at a medical conference last weekend as part of its effort to bring an oral antibody to market for IBD patients. The results come after...
View ArticleKallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial
Kallyope, a New York City biotech that has raised about $480 million over the past decade, quietly released results of its Phase 2 study in obesity in ...
View ArticleMerck mulls new site in Delaware; Granules India buys peptide CDMO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Merck has received a $30 million strategic fund from the state of...
View ArticleBayer CEO Bill Anderson previews 2025 turnaround plans
Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native felt like he was stuck in the same loop year after year. The company ...
View ArticleHansoh ends collaboration with Silence; Vir hunts for HBV drug partner
Plus, news about Alopexx, Medigene, EpimAb and Belite Bio: Hansoh backs out of siRNA pact with Silence Therapeutics: The London-based biotech said Hansoh has decided not to ...
View ArticleTeladoc reports $1B net loss as it works to turn around its business
Teladoc wrapped up its financial year with a $1 billion net loss and disappointing results as the telehealth giant continues to work on its turnaround strategy. The net loss was in a big part due ...
View ArticleVerve is latest gene editing company to suffer setback, as Vertex walks away...
Verve Therapeutics has not escaped the doom that seems to be engulfing the gene editing sector of late. The company said Thursday that Vertex Pharmaceuticals handed back the rights to a ...
View ArticleOpenAI meets cancer care
Most healthcare organizations have been using AI for decidedly unglamorous tasks like documentation and billing. Now we’re starting to see how it could be used in clinical care. Color Health and OpenAI...
View ArticleDrug policy veteran at CMS to depart on Friday
John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's leaving his agency on Friday. Coster, who has been at CMS for more than a...
View ArticlePharma-backed Mission Therapeutics stops preclinical operations, focuses on...
Clinical-stage biotech Mission Therapeutics is closing its preclinical laboratory operations in Cambridge, UK, a spokesperson confirmed to Endpoints News. The biotech will focus on its clinical...
View ArticleHHS’ vaccine injury panel in limbo after monthlong meeting delay
More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal compensation program for vaccine injuries has no information on when its operations...
View Article